Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?

Antiviral therapy - 1 Jan 2012

Ahlenstiel Golo, Booth David R, George Jacob

Abstract excerpt

In the past 2 years the ability to successfully eradicate chronic HCV infection has been substantially enhanced by two landmark scientific breakthroughs. Firstly, the advent of HCV-specific direct-acting antiviral (DAA) compounds has resulted in a significant increase in sustained virological response rates in HCV genotype-1-infected treatment-naive patients and in non-responders to prior pegylated interferon and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 23186615
DOI: 10.3851/IMP2427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?PMID 23186615Read ↗

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?Semantic proximity Read ↗

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Semantic proximity Read ↗

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?Semantic proximity Read ↗

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.Semantic proximity Read ↗

IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?Semantic proximity Read ↗

IL28B in the era of direct-acting antivirals for hepatitis C.Semantic proximity Read ↗

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?Semantic proximity Read ↗

Host genomics and HCV treatment response.Semantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Effect of IL28B genotype on hepatitis B and C virus infection.Semantic proximity Read ↗

Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Semantic proximity Read ↗

Hepatitis C pharmacogenetics: State of the art in 2010Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.